The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 02, 2024
Filed:
Feb. 24, 2022
Shaanxi Normal University, Xi'an, CN;
Yuan Zhang, Xi'an, CN;
Wenhui Qi, Xi'an, CN;
Xing Li, Xi'an, CN;
Bing Han, Xi'an, CN;
Peixin Shen, Xi'an, CN;
SHAANXI NORMAL UNIVERSITY, Xi'an, CN;
Abstract
An application of ellagic acid and a metabolic derivative urolithin compound thereof in preparation of an immunomodulatory medicine is provided. Classical animal models of autoimmunity and immunoregulation, such as experimental autoimmune encephalomyelitis, neuromyelitis optica mouse model, ulcerative colitis, and skin transplantation, are used as examples to conduct experiments from various aspects and perspectives, such as neurological function scores, histopathological changes of lesions, inflammatory factor expression, and pro-inflammatory cell numbers. The experiments demonstrate that ellagic acid and its metabolic derivatives significantly improved experimental autoimmune encephalomyelitis recovery and inhibited the infiltration of inflammatory cells into CNS, ameliorated experimental colitis severity and restored length of colon, reduced NMO-IgG-induced brain damage and prevented astrocyte loss and demyelination, as well as suppressed graft rejection and upregulated a proportion of regulatory T cells in order to enhance immune tolerance. Therefore, EA and its metabolic derivatives have high clinical application value and development prospect.